- Home
- NUVB vs PAXS Comparison
NUVB vs PAXS Comparison
Compare NUVB & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- PAXS
- Stock Information
- Founded
- NUVB 2018
- PAXS 2021
- Country
- NUVB United States
- PAXS United States
- Employees
- NUVB N/A
- PAXS N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- NUVB Health Care
- PAXS Finance
- Exchange
- NUVB Nasdaq
- PAXS Nasdaq
- Market Cap
- NUVB 679.9M
- PAXS 717.7M
- IPO Year
- NUVB N/A
- PAXS N/A
- Fundamental
- Price
- NUVB $2.10
- PAXS $15.17
- Analyst Decision
- NUVB Strong Buy
- PAXS
- Analyst Count
- NUVB 5
- PAXS 0
- Target Price
- NUVB $8.20
- PAXS N/A
- AVG Volume (30 Days)
- NUVB 3.2M
- PAXS 195.0K
- Earning Date
- NUVB 05-07-2025
- PAXS 01-01-0001
- Dividend Yield
- NUVB N/A
- PAXS 11.72%
- EPS Growth
- NUVB N/A
- PAXS N/A
- EPS
- NUVB N/A
- PAXS N/A
- Revenue
- NUVB $10,957,000.00
- PAXS N/A
- Revenue This Year
- NUVB $75.73
- PAXS N/A
- Revenue Next Year
- NUVB $440.21
- PAXS N/A
- P/E Ratio
- NUVB N/A
- PAXS N/A
- Revenue Growth
- NUVB N/A
- PAXS N/A
- 52 Week Low
- NUVB $1.54
- PAXS $12.57
- 52 Week High
- NUVB $3.97
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- NUVB 50.80
- PAXS 45.73
- Support Level
- NUVB $1.98
- PAXS $15.28
- Resistance Level
- NUVB $2.30
- PAXS $15.47
- Average True Range (ATR)
- NUVB 0.16
- PAXS 0.22
- MACD
- NUVB -0.01
- PAXS 0.03
- Stochastic Oscillator
- NUVB 21.43
- PAXS 23.89
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.